ABSTRACT
This guideline, mainly for nuclear medicine physicians contains recommendations in terms of procedure, reporting and interpretation in order to standardize Gallium-68 prostate specific membrane antigen (Ga-68 PSMA) positron emission tomography/computed tomography (PET/CT) imaging in prostate cancer (PC). It is thought that guideline recommendations, in which the current scientific place of Ga-68 PSMA PET/CT and developing indications are also discussed, will contribute to increase the accuracy and reliability of Ga-68 PSMA imaging in PC.
Keywords:
Ga-68 PSMA, PET/CT, staging, restaging
References
1
Fendler WP, Eiber M, Beheshti M, et al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging 2017;44:1014-1024.
2
Mottet N, Bellmunt J, Briers E. et al. Members of the EAU-ESTRO-ESUR-SIOG Prostate Cancer Guidelines Panel. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Edn. presented at the EAU Annual Congress Amsterdam 2020. 978-94-92671-07-3. Arnhem: EAU Guidelines Office; 2020.
3
Trabulsi EJ, Rumble RB, Jadvar H, et al. Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. J Clin Oncol 2020;38:1963-1996.
4
Ministry of Health, Public Health, General Directorate of Turkey Cancer Statistics 2015; Ankara, 2018. Available from: hsgm.saglik.gov.tr.
5
Siegel RL, Sahar L, Portier KM, et al. Cancer death rates in US congressional districts. CA Cancer J Clin 2015;65:339-344.
6
Bostwick DG. The pathology of early prostate cancer. CA Cancer J Clin 1989;39:376-393.
7
Gleason DF. Classification of prostate carcinoma. Cancer Chemother Rep 1966;50:125-128.
8
Gleason DF. Veterans Adminstration Cooperative Urological Research Group. 1977. Histologica grading and clinical staging of prostatic carcinoma. In: Urologic pathology: The prostate. editors Tannenbaum M: Lea & Febinger; Philadelphia. pp. 171-197.
9
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of grading paterns and proposal for a new grading system. Am J Surg Pathol 2016;40:244-252.
10
Moch H, Humphrey PA, Ulbright TM, Reuter V. WHO classification of tumours of the urinary system and male genital organs. Lyon, France: International Agency for Research on Cancer; 2016.
11
Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-935.
12
Heston WD. Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Urology 1997;49(Suppl 3A):104-112.
13
Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-85.
14
Hupe MC, Philippi C, Roth D, et al. Expression of prostate-specific membrane antigen (psma) on biopsies ıs an ındependent risk stratifier of prostate cancer patients at time of ınitial diagnosis. Front Oncol 2018;8:623.
15
Bravaccini S. Puccetti M, Bocchini M, et al. PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. Sci Rep 2018;8:4254.
16
Banerjee SR, Pullambhatla M, Byun Y, et al. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem 2010;53:5333-5341.
17
Eder M, Schafer M, Bauder-Wust U, et al. 68Ga -complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 2012;23:688-697.
18
Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The Theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med 2015;56:1697-1705.
19
Herrmann K, Bluemel C, Weineisen M, et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med 2015;56:855-861.
20
National Comprehensive Cancer Network. NCCN Clinical Guidelines in Oncology. Prostate Cancer. Version 2.2020. 2020; https://www.nccn.org/professionals/physician_gls/ pdf/prostate.pdf
21
Perera M, Papa N, Roberts M, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis Eur Urol 2019;77:403-417.
22
Radwan N, Phillips R, Ross A, et al. A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE). BMC Cancer 2017;17:453.
23
Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 2018;36:446-453. Published 2017, Jun 29.
24
Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 2007;14:531-547.
25
Parimi V, Goyal R, Poropatich K, Yang XJ. Neuroendocrine differentiation of prostate cancer: a review. Am J Clin Exp Urol 2014;2:273-285.
26
Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid (68)Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668-674.
27
Ceci F, Uprimny C, Nilica B, et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging 2015;42:1284-1294.
28
Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015;42:197-209.
29
Morigi JJ, Stricker PD, vanLeeuwen PJ, et al. Prospective comparison of 18F-Fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients Who have rising PSA after curative treatment and Are being considered for targeted therapy. J Nucl Med 2015;56:1185-1190.
30
Verburg FA, Pfister D, Heidenreich A, et al. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relationto PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging 2016;43:397-403.
31
Fendler WP, Calais J, Eiber M, et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol 2019;5:856-863.
32
Calais J, Fendler WP, Eiber M, et al. Impact of 68Ga-PSMA-11PET/CT on the management of prostate cancer patients with biochemical recurrence. J Nucl Med 2018;59:434-441.
33
Sonni I, Eiber M, Fendler WP, et al. Impact of 68Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single center study.J Nucl Med 2020;61:1153-1160.
34
Emmett L, van Leeuwen PJ, Nandurkar R, et al. Treatment Outcomes from (68)Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET. J Nucl Med 2017;58:1972-1976.
35
Calais J, Czernin J, Fendler WP, et al. Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. [published correction appears in BMC Cancer 2019;19:97 Published 2019 Jan 7.
36
Farolfi A, Gafita A, Calais J, et al. 68Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study. J Urol 2019;202:1174-1181.
37
Deandreis D, Guarneri A, Ceci F, et al. 68Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy. [published online ahead of print, 2020 Apr 20]. Eur J Nucl Med Mol Imaging 2020;10.1007/s00259-020-04809-8.
38
Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: aprospective, randomized, multicenter phase II trial. J Clin Oncol 2018;36:446-453.
39
Pyka T, Okamoto S, Dahlbender M, et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 2016;43:2114-21121.
40
Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic efficacy of (68) gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 2016;195:1436-1443.
41
Hijazi S, Meller B, Leitsmann C, et al. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/ computerized tomography. Prostate 2015;75:1934-1940.
42
Ferraro DA, Muehlematter UJ, Garcia Schüler HI, et al. (68)Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer. Eur J Nucl Med Mol Imaging 2020;47:147-159.
43
Öbek C, Doğanca T, Demirci E, et al. Members of Urooncology Association, Turkey. The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer. Eur J Nucl Med Mol Imaging 2017;44:1806-1812.
44
Dorff TB, Fanti S, Farolfi A, Reiter RE, Sadun TY, Sartor O. The evolving role of prostate-specific membrane antigen-based diagnostics and therapeutics in prostate cancer. Am Soc Clin Oncol Educ Book 2019;39:321-330.
45
Calais J, Kishan AU, Cao M, et al. Potential Impact of Ga-PSMA-11 PET/CT on the planning of definitive radiation therapy for prostate cancer. J Nucl Med 2018;59:1714-1721.
46
Schiller K, Devecka M, Maurer T, et al. Impact of Ga-PSMA-PET imaging on target volume definition and guidelines in radiation oncology-a patterns of failure analysis in patients with primary diagnosis of prostate cancer. Radiat Oncol 2018;13:36. https://doi.org/10.1186/s13014-018-0977-2.
47
Roach PJ, Francis RL, Emmett L, et al. The Impact of (68)Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. J Nucl Med 2018;59:82-88.
48
Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020;395:1208-1216.
49
Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011;11:411-425.
50
Høilund-Carlsen PF, Hess S, Werner TJ, Alavi A. Cancer metastasizes to the bone marrow and not to the bone: time for a paradigm shift! Eur J Nucl Med Mol Imaging 2018;45:893-897.
51
Ceci F, Fanti S. PSMA PET/CT imaging in prostate cancer: why and when. Clin Transl Imaging 2019:377-379.
52
Kratochwil C, Fendler WP, Eiber M, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging 2019;46:2536-2544.
53
Le JD, Tan N, Sholyar E, et al. Multifocality and prostate cancer detection by Multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol 2015;67:569-576.
54
Demirci E, Kabasakal L, Şahin OE, et al. Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer? Nucl Med Commun 2019;40:86-91.
55
Lopcia E, Lughezzanib G, Castelloa A, et al. Prospective Evaluation of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/ Computed Tomography in Primary Prostate Cancer Diagnosis. Eur Urol Focus 2020;S2405-4569:30092-30094.
56
Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 2016;34:1402-1418.
57
Schmuck S, von Klot CA, Henkenberens C, et al. Initial experience with volumetric 68Ga-PSMA I&T PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med 2017;58:1962-1968.
58
Seitz AK, Rauscher I, Haller B, et al. Preliminary results on response assessment using 68Ga-HBEDCC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. Eur J Nucl Med Mol Imaging 2018;45:602-612.
59
Schmidkonz C, Cordes M, Schmidt D, et al. 68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging 2018;45:1862-1872.
60
Kuten J, Sarid D, Yossepowitch O, Mabjeesh NJ, Even-Sapir E. [68Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up? EJNMMI Res 2019;9:84. Published 2019 Aug 29. doi:10.1186/s13550-019-0554-1.
61
Grubmüller B, Senn D, Kramer G, et al. Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2019;46:1063-1072.
62
Grubmüller B, Rasul S, Baltzer P, et al. Ressponse assessment using [68Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer. Prostate 2020;80:74-82.
63
Plouznikoff N, Artigas C, Sideris S, et al. Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients. Ann Nucl Med 2019;33:945-954.
64
Shaffer DR, Scher HI. Prostate cancer: a dynamic illness with shifting targets. Lancet Oncol 2003;4:407-414.
65
Wright Jr GL, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995;1:18-28.
66
Murga JD, Moorji SM, Han AQ, Magargal WW, DiPippo VA, Olson WC. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer. Prostate 2015;75:242-254.
67
Velikya I, 68Ga-based radiopharmaceuticals: Production and application relationship molecules 2015;20:12913-12943.
68
Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013;40:486-495.
69
Hacıosmanoğlu T, Demir M, Toklu T, et al. Quality control and acceptance tests of positron emission tomography (PET) systems. Nucl Med Semin 2020;6:51-70.
70
Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology 2007;50:472-483.
71
Demirci E, Sahin OE, Ocak M, Akovali B, Nematyazar J, Kabasakal L. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging. Nucl Med Commun 2016;37:1169-1179.
72
de Galiza Barbosa F, Queiroz MA, Nunes RF, et al. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging 2020;20:23. Published 2020 Mar 14.
73
Alçin G, Gündoğan C, Mutlu İN, Çermik TF. 68Ga-prostate-specific membrane antigen-11 pet/ct ı ncidental finding of a vestibular schwannoma. Clin Nucl Med 2019;44:883-885.
74
Evans MJ, Smith-Jones PM, Wongvipat J, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A 2011;108:9578-9582.
75
Kranzbühler B, Salemi S, Umbricht CA et al. Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells. Prostate 2018;78:758-765.
76
Zukotynski KA, Valliant J, Bénard F, et al. Flare on serial prostate-specific membrane antigentargeted 18F-DCFPyL PET/CT examinations in castration resistant prostate cancer: first observations. Clin Nucl Med 2018;43:213-216.
77
Aggarwal R, Wei X, Kim W, et al. Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer. Eur Urol Oncol 2018;1:78-82.
78
Eiber M, Herrmann K, Calais J, et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. J Nucl Med 2018;59:469-478.
